Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Insiders Show Strong Belief in Charles Colvard Ltd

Elaine Mendonca by Elaine Mendonca
March 4, 2024
in Breaking News
0
TMUS stock news
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Insiders within Charles & Colvard, Ltd. have recently been increasing their holdings, showing strong belief in the company’s potential. Director Ollin B Sykes bought 44,940 shares at an average price of $0.38, totaling approximately $17,287. President and CEO Don O’Connell also acquired 30,000 shares at an average price of $0.34, costing around $10,164. These insider trades indicate optimism for the future of Charles & Colvard, even after the company reported a quarterly loss of 9 cents per share on February 13th.

CTHR Stock Price Jumps 3.38% on March 4, 2024: Is This the Start of a Trend?

On March 4, 2024, CTHR stock experienced a positive price momentum, with shares increasing by $0.01 since the previous market close. This represents a 3.38% rise in the stock price, opening at $0.36, which was $0.01 higher than its previous close.

Investors should take note of the price movement on March 4 and consider whether this short-term increase is indicative of a larger trend or simply a temporary fluctuation. It is important to conduct thorough research and analysis before making any investment decisions regarding CTHR or any other stock.

CTHR Stock Performance Under Scrutiny: Revenue Decline and Net Loss Reported

On March 4, 2024, the stock performance of CTHR, or Charles & Colvard, was under scrutiny as the company released its financial data for the past year and the most recent quarter. According to CNN Money, CTHR reported a total revenue of $29.95 million for the past year, which was a decrease of 30.5% compared to the previous year. The total revenue for the most recent quarter was $7.91 million, showing a significant increase of 59.61% since the last quarter.

In terms of net income, CTHR reported a net loss of $19.58 million for the past year, which was a substantial decrease of 924.83% compared to the previous year. The net loss for the most recent quarter was $2.87 million, representing a decrease of 12.86% since the last quarter.

Earnings per share (EPS) for CTHR were also negatively impacted, with the company reporting an EPS of -$0.64 for the past year, a decrease of 950.4% compared to the previous year. The EPS for the most recent quarter was -$0.09, showing a decrease of 13.19% since the last quarter.

Overall, the financial data released by CTHR on March 4, 2024, painted a mixed picture of the company’s performance. Investors and analysts will be closely monitoring CTHR’s future financial reports to see if the company can turn around its negative performance and improve its bottom line.

Tags: CTHR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_ Charts for stock trading

Analyst Evaluations and Price Targets for Analog Devices NASDAQ ADI

Entertainment Trading online

Netflixs Triumph A ForwardThinking Approach to Streaming Success

Entertainment Markets and money

Disneys Strategic Initiatives for Success and Sustainability

Recommended

Baidu Stock

Baidu’s Strategic Moves in Autonomous Driving and AI Draw Mixed Investor Reactions

1 month ago

Windtree Therapeutics Achieves Financial Stability and Advances Clinical Programs

2 years ago
Technology Data analytics Stock Bull Market

Anticipation High for Adobes FirstQuarter Financial Results and AI Innovation

2 years ago
Ideaya Biosciences Stock

Ideaya Biosciences: A Tale of Market Skepticism and Clinical Promise

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

AES Shares Surge on Potential $38 Billion Acquisition Speculation

Kura Oncology Investors Await Crucial FDA Verdict

Cadence Design Stock: A Battle Between Fundamentals and Market Signals

Trending

DuPont de Nemours Stock
Analysis

DuPont Faces Critical Test as Quarterly Results Loom

by Dieter Jaworski
November 6, 2025
0

DuPont de Nemours finds itself at a pivotal moment as the chemical giant prepares to release quarterly...

Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025
Emerson Electric Stock

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

November 6, 2025
Lanzatech Global Stock

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

November 6, 2025
Darden Restaurants Stock

Is Darden Restaurants Facing a Critical Test?

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • DuPont Faces Critical Test as Quarterly Results Loom
  • Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure
  • Emerson Electric’s Strategic Pivot Faces Market Scrutiny

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com